Global Antibody Drug Conjugate Market Outlook 2020
Global Antibody Drug Conjugate Market Outlook 2020

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

**We look forward to being of service to you.**

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone: +44 (0)7887 945155** or **Email: pdb@bioportfolio.co.uk**
Global Antibody Drug Conjugate Market Outlook 2020

Antibody drug conjugates are the new age therapeutic agents. These are examples of immunoconjugates and bioconjugates. They combine the unique targeting property of monoclonal antibodies and the cancer cell killing ability of cytotoxic drugs. This concept of a “magic bullet” to deliver cytotoxic therapy to the site of a tumor has been envisioned for a century. But its success has become possible only now with the recent technological advancements. The recent approvals of ADCETRIS and Kadcyla followed by various Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in the ADC industry.

According to this edition of the report “Global Antibody Drug Conjugate Market Outlook 2020”, the ADC market is anticipated to reach around US$ 12.7 Billion by 2020. In our report, there is a detailed analysis of the market for ADCETRIS and Kadcyla. An estimation of the market potential of these drugs has been done keeping in mind that these drugs are being tested in clinical trials for various indications, apart from the ones which are already approved. The mentioned ADCs will take some time to show their complete market potential, we believe.

Moreover, in our report we have provided information about the ADCs at various stages of clinical development. We have highlighted the various cancer indications that these ADCs target and the cytotoxic drugs that are commonly used for their development. Apart from this, the study provides comprehensive analysis of various ADCs in advanced stages of development. In addition, the report highlights the major drivers and challenges, latest trends and developments and strategic collaborations impacting the industry’s growth.

The latter part of the report discusses some of the prominent players in the ADC market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Moreover, comparative analyses of their strengths and weaknesses have also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.

Additional Details

Publisher : RNCOS
Reference : 
Number of Pages : 80
Report Format : PDF
Publisher Information :
RNCOS is a Business Consulting Service firm providing multiple services to companies wishing to engage in any business expansion.

We uniquely position our self as a "one-stop-shop" offering a broad spectrum of Management Consulting and Business facilitation services including but not limited to Financial & Business Assessment, Market Entry / Expansion Strategies, Market and Industry Research, Identification & Selection of Business Partners, Feasibility and Facility Location Studies etc.

Since our inception in 2002, we have gained industry experience and expertise in offering research solutions to distinguished clientele across multi geographies and industry verticals. We help our clients in achieving sustainable performance and better growth prospects by weeding out their obsolete business process with well laid strategies by working in close co-ordination with them.

Be it market entry, product testing, competition assessment, customer satisfaction study, pricing analysis or any other requirement, RNCOS team acts proactively to fit in the best possible solution for our valued clients. We believe in multi-level client interaction and complete transparency from the project commencement till effective implementation, thus ensuring total customer satisfaction.
Table Of Contents for Global Antibody Drug Conjugate Market Outlook 2020 [Published by RNCOS]

- 1. Analyst View
- 2. Research Methodology
- 3. Antibody Drug Conjugate (ADC) - An Introduction
- 4. ADC Market Outlook to 2020
  - 4.1 ADCETRIS
    - 4.1.1 Market Potential
    - 4.1.2 Market Size and Forecasts to 2020
  - 4.2 Kadcyla
    - 4.2.1 Market Potential
    - 4.2.2 Market Size and Forecasts to 2020
- 5. ADC Pipeline Analysis
- 6. By Phase
- 7. By Indication
- 8. By Drug
- 9. Drivers and Challenges
- 10. Drivers
- 11. Challenges
- 12. Current Status of Potential ADCs in Pipeline
- 15. Indatuximab Ravtansine/BT-062 - Bioteest
- 16. Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
- 17. Polatuzumab Vedotin/RG7596 - Roche Genentech
- 18. Pinatuzumab Vedotin/RG7593 - Roche Genentech
- 19. Lifastuzumab Vedotin/RG7599 - Roche Genentech
- 20. Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
- 21. Inotuzumab Ozogamicin (CMC-544) - Pfizer
- 22. Trends and Developments
- 23. ADC at the Forefront to Treat Hematological Malignancies
- 24. ADCs Providing Advantages to Breast Cancer Patients
- 25. Strategic Collaborations in the ADC Industry
- 26. Competitive Assessment
- 27. Seattle Genetics
- 28. Bayer Healthcare
- 29. Novartis
- 30. Immunomedics
- 31. Agensys
- 32. List of Figures
- 33. List of Tables

How to Buy...

Global Antibody Drug Conjugate Market Outlook 2020 [Published by RNCOS]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/24726

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk
or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: .............................................................................................................
Job Title: ..................................................................................................................
Your Email: ..............................................................................................................
Your Contact Phone: ..............................................................................................
Company Name: ....................................................................................................
Address: ..................................................................................................................
Post/Zip Code: ...........................................................................................................
Country: ...................................................................................................................
P.O. Number: ...........................................................................................................
Any Other Instructions: ..........................................................................................

Pricing Options: (please tick one)
○ &‘#&#36;‰1200 | Single User Price
○ &‘#&#36;‰1700 | Multi User Price

Payment Options: (please tick one)
○ Online Credit Card (we will email you the invoice with a payment link)
○ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ..........................................................................................

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.